Sinclair T S, Booth N A, Penman S M, Brunt P W, Mowat N A, Bennett N B
Dept. of Medicine, Aberdeen Royal Infirmary, Scotland.
Scand J Gastroenterol. 1988 Jun;23(5):620-4. doi: 10.3109/00365528809093922.
Measurements of the principal protease inhibitors were carried out in patients with two types of chronic liver disease: alcoholic cirrhosis and primary biliary cirrhosis. Measurement of the two major protease inhibitors operative in the haemostatic mechanism--that is, antithrombin III and alpha 2-antiplasmin--showed significantly reduced levels in the alcoholic cirrhosis group, who satisfied clinical and biochemical criteria of impaired hepatocellular function, but not in the primary biliary cirrhosis group, who had relatively good preservation of hepatocellular function. Significant correlation of levels of both these major protease inhibitors with the serum albumin concentration was also found. No evidence of disseminated intravascular coagulation was detected, and therefore failure of synthesis by the liver is the likely explanation of the low levels noted.
对患有两种慢性肝病（酒精性肝硬化和原发性胆汁性肝硬化）的患者进行了主要蛋白酶抑制剂的测量。对止血机制中起作用的两种主要蛋白酶抑制剂——即抗凝血酶III和α2 - 抗纤溶酶进行测量，结果显示，在满足肝细胞功能受损临床和生化标准的酒精性肝硬化组中，这两种抑制剂的水平显著降低，而在肝细胞功能相对保存良好的原发性胆汁性肝硬化组中则未出现这种情况。还发现这两种主要蛋白酶抑制剂的水平与血清白蛋白浓度之间存在显著相关性。未检测到弥散性血管内凝血的迹象，因此肝脏合成功能衰竭可能是所观察到的低水平的原因。
